Jacobson 2010b.

Methods	Randomized, double‐blind, placebo‐controlled, parallel‐group study Randomization: method not specified Allocation concealment: unclear Blinding: the objects that were blinded to were not mentioned Maximum follow‐up: 58 days
Participants	Age of ≧ 18 years, plasma HIV‐1 RNA level of ≧ 5000 copies/mL, CD4+ lymphocyte counts of ≧ 300/μl and no documented count being 250/μL, no antiretroviral therapy for ≧ 12 weeks, no history of an AIDS‐defining illness, and only R5 HIV‐1 detectable in the original Trofile assay (Monogram Biosciences, Inc.)
Interventions	Single IV doses of 10 mg/kg (N = 10) Single IV doses of 5 mg/kg (N = 10) Placebo (N = 11)
Outcomes	Antiviral effects (Change in HIV‐1 RNA level from baseline, log10 copies/mL; the proportion of subjects with ≧ 1 log10 copies/mL decrease in HIV RNA level; the proportion of subjects with ≧ 2 log10 copies/mL decrease in HIV RNA level; change in CD4 cell count on at days 8, 12, 15, and 22, cells/μL) Safety (adverse events): headache, nasal congestion and pruritus
Notes	Potential conflicts of interest: some authors are current or past employees of Progenics Pharmaceuticals and may hold stock or stock options in the company Financial support: National Institutes of Health (Public Health Service grant AI066329)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not specified
Allocation concealment (selection bias)	Unclear risk	This article did not mention
Selective reporting (reporting bias)	Unclear risk	Unclear
Other bias	Unclear risk	Unclear
Blinding	Unclear risk	The objects that were blinded to were not mentioned
Incomplete outcome data addressed	Unclear risk	Unclear

AIDS: acquired immune deficiency syndrome; HIV: human immunodeficiency virus; IV: intravenous; N: number of patients